- Home
- PHAR vs NXRT Comparison
PHAR vs NXRT Comparison
Compare PHAR & NXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- NXRT
- Stock Information
- Founded
- PHAR 1988
- NXRT 2014
- Country
- PHAR Netherlands
- NXRT United States
- Employees
- PHAR N/A
- NXRT N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- NXRT Real Estate Investment Trusts
- Sector
- PHAR Health Care
- NXRT Real Estate
- Exchange
- PHAR Nasdaq
- NXRT Nasdaq
- Market Cap
- PHAR 798.2M
- NXRT 804.1M
- IPO Year
- PHAR N/A
- NXRT N/A
- Fundamental
- Price
- PHAR $13.70
- NXRT $33.54
- Analyst Decision
- PHAR Strong Buy
- NXRT Hold
- Analyst Count
- PHAR 3
- NXRT 6
- Target Price
- PHAR $30.00
- NXRT $40.88
- AVG Volume (30 Days)
- PHAR 12.8K
- NXRT 197.5K
- Earning Date
- PHAR 07-31-2025
- NXRT 07-29-2025
- Dividend Yield
- PHAR N/A
- NXRT 6.32%
- EPS Growth
- PHAR N/A
- NXRT N/A
- EPS
- PHAR N/A
- NXRT N/A
- Revenue
- PHAR $339,836,000.00
- NXRT $254,446,000.00
- Revenue This Year
- PHAR $12.88
- NXRT N/A
- Revenue Next Year
- PHAR $8.54
- NXRT $5.28
- P/E Ratio
- PHAR N/A
- NXRT N/A
- Revenue Growth
- PHAR 22.44
- NXRT N/A
- 52 Week Low
- PHAR $6.73
- NXRT $29.98
- 52 Week High
- PHAR $17.08
- NXRT $48.37
- Technical
- Relative Strength Index (RSI)
- PHAR 67.43
- NXRT 60.32
- Support Level
- PHAR $12.13
- NXRT $31.81
- Resistance Level
- PHAR $12.76
- NXRT $32.63
- Average True Range (ATR)
- PHAR 0.89
- NXRT 0.74
- MACD
- PHAR 0.13
- NXRT 0.28
- Stochastic Oscillator
- PHAR 44.41
- NXRT 97.90
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About NXRT NexPoint Residential Trust Inc.
NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.